tbuckley/cabot-search huggingface dataset:
Abstract P4-07-06: Circulating lipids and breast cancer survival in the Malmö diet and cancer study
Authors: Sixten Harborg, Thomas P Ahern, Maria Feldt, Ann H Rosendahl, Deirdre Cronin-Fenton, Olle Melander, Signe Borgquist
Journal: Cancer Research (2022)

Abstract Rationale: Overweight and obesity are associated with inferior prognosis in breast cancer. The explanation is considered multifactorial, and dyslipidemia may be a contributing factor. The purpose of this study was to examine the association between circulating lipids and breast cancer outcomes in patients enrolled in the Malmö Diet and Cancer Study (MDCS). Patients and methods: Circulating lipid levels were measured in the blood sampled upon enrollment in the female MDCS cohort (N=17,035). We identified all MDCS participants with incident invasive breast cancer diagnosed between 1991-2014. The follow-up time began at breast cancer diagnosis and continued until the first event of breast cancer recurrence, death, emigration, or five years of follow-up. We estimated the incidence rates of recurrence at five years and fit Cox regression models to compute crude and adjusted hazard ratios (HRs) with 95% confidence intervals (95% CI) of breast cancer recurrence as well as all-cause mortality according to cohort-specific tertiles of apolipoprotein A-1 (Apo A-1) and apolipoprotein B (Apo B). Results: We enrolled 850 eligible patients. During the five years of follow up, 90 invasive recurrences with over 3,807 person-years occurred. In multivariable analyses, high levels of Apo B were associated with an increased rate of recurrence (tertile 3 vs. 1, HR= 2.30 [95% CI: 1.13-4.68]). However, high levels of Apo B were not associated with all-cause mortality (tertile 3 vs. 1, HR= 1.23 [95%CI: 0.68-2.25]). We observed no associations between levels of Apo A-1 and recurrence (tertile 3 vs. 1, HR= 1.34 [95%CI: 0.70-2.58]) or all-cause mortality (tertile 3 vs. 1, HR=1.12 [95%CI: 0.61-2.05]). Conclusion: High pre-diagnostic levels of Apo B were associated with an increased risk of recurrence among breast cancer patients. Circulating Apo A-1 was not associated with breast cancer outcome. These results warrant further investigation into the importance of lipid-regulation in breast cancer patients. Citation Format: Sixten Harborg, Thomas P Ahern, Maria Feldt, Ann H Rosendahl, Deirdre Cronin-Fenton, Olle Melander, Signe Borgquist. Circulating lipids and breast cancer survival in the Malmö diet and cancer study [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P4-07-06.
THE EFFECT OF INCLISIRAN IN PATIENTS WITH PRIOR MYOCARDIAL INFARCTION: A POST HOC POOLED ANALYSIS FROM THE ORION-10 AND ORION-11 RANDOMIZED CONTROLLED TRIALS
Authors: Ulf Landmesser, David G. Kallend, Wolfgang Koenig, Lawrence A. Leiter, Frederick J. Raal, Kausik Kumar Ray, Scott Wright, YannTong Chiang, Lorena Garcia Conde Orozco
Journal: Journal of the American College of Cardiology (2022)
Abstract TF2-1: A journey through the life of HER2: How did we get here and where are we going?
Authors: K Blenman
Journal: Cancer Research (2022)

Abstract After the discovery in the early 1980s that human epidermal growth factor receptor 2 (HER2; ERBB2) could trigger exaggerated cell growth and division, it eventually became clear that blocking this protein could slow or stop some types of breast cancer. Since then, several HER2 inhibitors have been USA FDA approved. However, despite this breakthrough success, many HER2-positive breast cancer patients do not benefit from these therapies, or they initially benefit but become resistant over time. Here we discuss the details of the heterogeneity in response, resistance mechanisms/signaling, alternative HER2q activation mechanisms (mutation), and heterogeneity in amplicon structure and does it matter. Citation Format: K Blenman. A journey through the life of HER2: How did we get here and where are we going? [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr TF2-1.
ENDOVASCULAR INTRAVASCULAR LITHOTRIPSY WITH ADJUNCT DRUG-COATED BALLOON ANGIOPLASTY AND/OR ATHERECTOMY IN THE TREATMENT OF COMMON FEMORAL ARTERY DISEASE: A CASE SERIES WITH AN 18-MONTH FOLLOW-UP
Authors: Muhammad Baig, Ammer Aldairi, Michael Kwok, Mohammad Saud Khan, Kyari Sumayin Ngamdu, Nasir Iqbal, Hafiz M. Imran, Omar Hyder, Herbert D. Aronow, Peter A. Soukas
Journal: Journal of the American College of Cardiology (2022)
Simplified hypertension screening methods across 60 countries: An observational study
Authors: Rodrigo M. Carrillo-Larco, Wilmer Cristobal Guzman-Vilca, Dinesh Neupane
Journal: PLoS Medicine (2022)

Background Simplified blood pressure (BP) screening approaches have been proposed. However, evidence is limited to a few countries and has not documented the cardiovascular risk amongst missed hypertension cases, limiting the uptake of these simplified approaches. We quantified the proportion of missed, over-diagnosed, and consistently identified hypertension cases and the 10-year cardiovascular risk in these groups. Methods and findings We used 60 WHO STEPS surveys (cross-sectional and nationally representative; n = 145,174) conducted in 60 countries in 6 world regions between 2004 and 2019. Nine simplified approaches were compared against the standard (average of the last 2 of 3 BP measurements). The 10-year cardiovascular risk was computed with the 2019 World Health Organization Cardiovascular Risk Charts. We used t tests to compare the cardiovascular risk between the missed and over-diagnosed cases and the consistent hypertension cases. We used Poisson multilevel regressions to identify risk factors for missed cases (adjusted for age, sex, body mass index, and 10-year cardiovascular risk). Across all countries, compared to the standard approach, the simplified approach that missed the fewest cases was using the second BP reading if the first BP reading was 130–145/80–95 mm Hg (5.62%); using only the second BP reading missed 5.82%. The simplified approach with the smallest over-diagnosis proportion was using the second BP reading if the first BP measurement was ≥140/90 mm Hg (3.03%). In many countries, cardiovascular risk was not significantly different between the missed and consistent hypertension groups, yet the mean was slightly lower amongst missed cases. Cardiovascular risk was positively associated with missed hypertension depending on the simplified approach. The main limitation of the work is the cross-sectional design. Conclusions Simplified BP screening approaches seem to have low misdiagnosis rates, and cardiovascular risk could be lower amongst missed cases than amongst consistent hypertension cases. Simplified BP screening approaches could be included in large screening programmes and busy clinics.
Establishment and recall of SARS-CoV-2 spike epitope-specific CD4+ T cell memory
Authors: Kathleen M. Wragg, Wen Shi Lee, Marios Koutsakos, Hyon-Xhi Tan, Thakshila Amarasena, Arnold Reynaldi, Grace Gare, Penny Konstandopoulos, Kirsty R. Field, Robyn Esterbauer, Helen E. Kent, Miles P. Davenport, Adam K. Wheatley, Stephen J. Kent, Jennifer A. Juno
Journal: Nature Immunology (2022)
Multiple Profile Models Extract Features from Protein Sequence Data and Resolve Functional Diversity of Very Different Protein Families
Authors: R. Vicedomini, J.P. Bouly, E. Laine, A. Falciatore, A. Carbone
Journal: Molecular Biology and Evolution (2022)

Functional classification of proteins from sequences alone has become a critical bottleneck in understanding the myriad of protein sequences that accumulate in our databases. The great diversity of homologous sequences hides, in many cases, a variety of functional activities that cannot be anticipated. Their identification appears critical for a fundamental understanding of the evolution of living organisms and for biotechnological applications. ProfileView is a sequence-based computational method, designed to functionally classify sets of homologous sequences. It relies on two main ideas: the use of multiple profile models whose construction explores evolutionary information in available databases, and a novel definition of a representation space in which to analyze sequences with multiple profile models combined together. ProfileView classifies protein families by enriching known functional groups with new sequences and discovering new groups and subgroups. We validate ProfileView on seven classes of widespread proteins involved in the interaction with nucleic acids, amino acids and small molecules, and in a large variety of functions and enzymatic reactions. ProfileView agrees with the large set of functional data collected for these proteins from the literature regarding the organization into functional subgroups and residues that characterize the functions. In addition, ProfileView resolves undefined functional classifications and extracts the molecular determinants underlying protein functional diversity, showing its potential to select sequences towards accurate experimental design and discovery of novel biological functions. On protein families with complex domain architecture, ProfileView functional classification reconciles domain combinations, unlike phylogenetic reconstruction. ProfileView proves to outperform the functional classification approach PANTHER, the two k-mer-based methods CUPP and eCAMI and a neural network approach based on Restricted Boltzmann Machines. It overcomes time complexity limitations of the latter.
THE BURDEN OF CHRONIC CARDIOVASCULAR COMORBIDITIES IN SEXUAL MINORITY POPULATIONS: ANALYSIS FROM THE NATIONWIDE INPATIENT SAMPLE DATABASE
Authors: Neelkumar Patel, Binita Ghosh, Adrija Hajra, Dhrubajyoti Bandyopadhyay, Sandipan Chakraborty, Birendra Amgai, Amandeep Goyal, Tarun Dalia
Journal: Journal of the American College of Cardiology (2022)
CAUSES AND PREDICTORS OF 30-DAY READMISSION AFTER PACEMAKER INSERTION FOR ATRIOVENTRICULAR BLOCK: AN ANALYSIS OF THE NATIONAL READMISSIONS DATABASE
Authors: Sreeram Yalamanchili, Ramtej Atluri, Sujitha Velagapudi, Mukunthan Murthi, Bharosa Sharma, Hafeez Shaka
Journal: Journal of the American College of Cardiology (2022)
Prognoses of patients with melanoma who continue/discontinue anti-programmed death-1 therapy after achieving a complete response in a real-world setting: a multicentre retrospective study
Authors: Junji Kato, Kenjiro Namikawa, Jiro Uehara, Motoo Nomura, Yasuhiro Nakamura, Hisashi Uhara, Hiroshi Uchi, Shusuke Yoshikawa, Yukiko Kiniwa, Yoshiyuki Nakamura, Takuya Miyagawa, Shigeto Matsushita, Tatsuya Takenouchi, Naohito Hatta, Fumitaka Ohno, Taku Maeda, Satoshi Fukushima, Naoya Yamazaki
Journal: British Journal of Dermatology (2022)

Abstract
The Lancet Breast Cancer Commission: tackling a global health, gender, and equity challenge
Authors: Charlotte Elizabeth Coles, Benjamin O Anderson, David Cameron, Fatima Cardoso, Richard Horton, Felicia Marie Knaul, Miriam Mutebi, Naomi Lee, Jean E Abraham, Benjamin O Anderson, Fabrice André, Carlos H Barrios, Judith M Bliss, Judy C Boughey, David A Cameron, Fatima V Cardoso, Lisa A Carey, Sanjoy Chatterjee, Charlotte E Coles, Jack Cuzick, Dorothy Du Plooy, Prudence A Francis, Julie R Gralow, Reshma Jagsi, Felicia M Knaul, Fei Ma, Ritse M Mann, Stuart A McIntosh, Shirley A Mertz, Miriam Mutebi, Funmi Olopade, Kelly-Anne Phillips, Philip M Poortmans, Tanja Spanic, Dingle Spence, Hilary Stobart, Fraser WF Symmans, Cynthia Villarreal-Garza, Cheng-Har Yip, Maya J Bienz, Lynsey M Drewett, Alex Fulton, Dharrnesha Inbah Rajah, Farasat Kazmi, Jeffrey Rubasingham, Mareike Thompson, Valentina Vargas, Hector Arreola, Raj A Badwe, Renzo JC Calderon Anyosa, Rajiv V Dave, Ama De-Graft Aikins, Helena M Earl, Beverley M Essue, Ruth B Etzioni, Sarah T Hawley, Xiaoxiao Jiang, Indraneel Mittra, Patricia I Moreno, Renu Sara Nargund, Cara Noble, Robert A Smith, Didier Verhoeven, Jiani N Wang, David A Watkins, Brian J Zikmund-Fisher
Journal: The Lancet (2022)
Abstract P4-05-08: 18F-FDG uptake of visceral adipose tissue on preoperative PET/CT as a predictive marker for breast cancer recurrence
Authors: Pill Sun Paik, Chang Ik Yoon, Hyun Jeong Kim, Yoon Jin Cha, Dooreh Kim, Soong June Bae, Sung Gwe Ahn, Joon Jeong, Woo-Chan Park, Young Hoon Ryu, Tae Joo Jeon, Chai Won Kim
Journal: Cancer Research (2022)

Abstract Background: Glucose utilisation of visceral adipose tissue (VAT) reflects inflammatory activities, which promote tumour cell growth and carcinogenesis. The impact of the VAT-inflammatory response on survival outcomes in breast cancer is not known. We investigated survival outcomes in breast cancer patients based on the standardised uptake value (SUV) in VAT using 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET/CT). Methods: We retrospectively enrolled breast cancer patients (stages I-III) treated at the Gangnam Severance Hospital between 2007 and 2010. Metabolic activities of VAT and tumour were calculated based on FDG uptake, and the clinical characteristics and survival outcomes were comparatively analysed in the high-SUV and low-SUV groups. Results: The SUV of VAT (SUV-VAT) was obtained for 148 patients. With no significant intergroup differences in clinical characteristics, high SUV-VAT was associated with poor recurrence-free survival (RFS; hazard ratio [HR] 2.754, 95% confidence interval [CI] 1.090-6.958, P=0.032) and distant metastasis-free survival (DMFS; HR 3.500, 95% CI 1.224-10.01, P=0.019). Multivariate analysis showed that high SUV-VAT was a significant clinical factor for both poor RFS and DMFS (P=0.023 and P=0.039, respectively). SUV-tumour was significantly associated with RFS (P=0.0388), but not DMFS (P=0.0718). Conclusion: The glucose metabolism of VAT, assessed by 18F-FDG PET/CT, is a prognostic biomarker of adverse outcomes and of primary tumour metabolism in breast cancer. The glucose utilisation of VAT may reflect the degree of inflammation associated with breast cancer recurrence and metastasis. Keywords: breast cancer, visceral adipose tissue, inflammation, 18F-FDG, PET/CT, glycolysis, metastasis, recurrence Citation Format: Pill Sun Paik, Chang Ik Yoon, Hyun Jeong Kim, Yoon Jin Cha, Dooreh Kim, Soong June Bae, Sung Gwe Ahn, Joon Jeong, Woo-Chan Park, Young Hoon Ryu, Tae Joo Jeon, Chai Won Kim. 18F-FDG uptake of visceral adipose tissue on preoperative PET/CT as a predictive marker for breast cancer recurrence [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P4-05-08.
Secondary influenza challenge triggers resident memory B cell migration and rapid relocation to boost antibody secretion at infected sites
Authors: Andrew J. MacLean, Niamh Richmond, Lada Koneva, Moustafa Attar, Cesar A.P. Medina, Emily E. Thornton, Ariane Cruz Gomes, Aadil El-Turabi, Martin F. Bachmann, Pramila Rijal, Tiong Kit Tan, Alain Townsend, Stephen N. Sansom, Oliver Bannard, Tal I. Arnon
Journal: Immunity (2022)

Resident memory B (BRM) cells develop and persist in the lungs of influenza-infected mice and humans; however, their contribution to recall responses has not been defined. Here, we used two-photon microscopy to visualize BRM cells within the lungs of influenza -virus immune and reinfected mice. Prior to re-exposure, BRM cells were sparsely scattered throughout the tissue, displaying limited motility. Within 24 h of rechallenge, these cells increased their migratory capacity, localized to infected sites, and subsequently differentiated into plasma cells. Alveolar macrophages mediated this process, in part by inducing expression of chemokines CXCL9 and CXCL10 from infiltrating inflammatory cells. This led to the recruitment of chemokine receptor CXCR3-expressing BRM cells to infected regions and increased local antibody concentrations. Our study uncovers spatiotemporal mechanisms that regulate lung BRM cell reactivation and demonstrates their capacity to rapidly deliver antibodies in a highly localized manner to sites of viral replication.
Outcomes of SARS-CoV-2 infection among children and young people with pre-existing rheumatic and musculoskeletal diseases
Authors: Lianne Kearsley-Fleet, Min-Lee Chang, Saskia Lawson-Tovey, Ruth Costello, Šárka Fingerhutová, Natálie Švestková, Alexandre Belot, Florence A Aeschlimann, Isabelle Melki, Isabelle Koné-Paut, Sascha Eulert, Tilmann Kallinich, Yackov Berkun, Yosef Uziel, Bernd Raffeiner, Filipa Oliveira Ramos, Daniel Clemente, Christina Dackhammar, Nico M Wulffraat, Helen Waite, Anja Strangfeld, Elsa F Mateus, Pedro M Machado, Marc Natter, Kimme L Hyrich
Journal: Annals of the Rheumatic Diseases (2022)

<h3>Objectives</h3> Some adults with rheumatic and musculoskeletal diseases (RMDs) are at increased risk of COVID-19-related death. Excluding post-COVID-19 multisystem inflammatory syndrome of children, children and young people (CYP) are overall less prone to severe COVID-19 and most experience a mild or asymptomatic course. However, it is unknown if CYP with RMDs are more likely to have more severe COVID-19. This analysis aims to describe outcomes among CYP with underlying RMDs with COVID-19. <h3>Methods</h3> Using the European Alliance of Associations for Rheumatology COVID-19 Registry, the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry, and the CARRA-sponsored COVID-19 Global Paediatric Rheumatology Database, we obtained data on CYP with RMDs who reported SARS-CoV-2 infection (presumptive or confirmed). Patient characteristics and illness severity were described, and factors associated with COVID-19 hospitalisation were investigated. <h3>Results</h3> 607 CYP with RMDs &lt;19 years old from 25 different countries with SARS-CoV-2 infection were included, the majority with juvenile idiopathic arthritis (JIA; n=378; 62%). Forty-three (7%) patients were hospitalised; three of these patients died. Compared with JIA, diagnosis of systemic lupus erythematosus, mixed connective tissue disease, vasculitis, or other RMD (OR 4.3; 95% CI 1.7 to 11) or autoinflammatory syndrome (OR 3.0; 95% CI 1.1 to 8.6) was associated with hospitalisation, as was obesity (OR 4.0; 95% CI 1.3 to 12). <h3>Conclusions</h3> This is the most significant investigation to date of COVID-19 in CYP with RMDs. It is important to note that the majority of CYP were not hospitalised, although those with severe systemic RMDs and obesity were more likely to be hospitalised.
INTRACARDIAC MASS AS AN INITIAL MANIFESTATION OF BEHÇET'S DISEASE
Authors: Carlos Eduardo Lucena Montenegro, Renata Amorim de Lucena, Maria de Fátima Oliveira da Silva Filha, Bárbara Mariana dos Santos Silva, Raquel Cristina Farias de Medeiros Queiroz, Leoncio Bem Sidrim, Caio Cézar Gomes Rezende, Rodrigo Gusmão de Albuquerque Miranda, Larissa Costa Lira da Silva, Rodrigo Brito de Barros Correia e Silva, Lucas Eduardo Vilarinho Guimarães, Tawanna Xavier Marques de Carvalho
Journal: Journal of the American College of Cardiology (2022)
Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
Authors: Julie Westerlin Kjeldsen, Cathrine Lund Lorentzen, Evelina Martinenaite, Eva Ellebaek, Marco Donia, Rikke Boedker Holmstroem, Tobias Wirenfeldt Klausen, Cecilie Oelvang Madsen, Shamaila Munir Ahmed, Stine Emilie Weis-Banke, Morten Orebo Holmström, Helle Westergren Hendel, Eva Ehrnrooth, Mai-Britt Zocca, Ayako Wakatsuki Pedersen, Mads Hald Andersen, Inge Marie Svane
Journal: Nature Medicine (2022)

In the version of this article initially published, a composition error appeared in the second sentence of the Fig. 1 caption.In the text now reading "Microbial pathways related to short-chain fatty acid (SCFA) metabolism are already reduced and those related to branched-chain amino acid (BCAA) metabolism increased in metabolically matched controls relative to healthy controls, prior to IHD diagnosis, " the terms "reduced" and "increased" were reversed.The error has been corrected in the HTML and PDF versions of the article.
Venetoclax Cooperates with Ionizing Radiation to Attenuate Diffuse Midline Glioma Tumor Growth
Authors: Krishna Madhavan, Ilango Balakrishnan, Senthilnath Lakshmanachetty, Angela Pierce, Bridget Sanford, Susan Fosmire, Hanan B. Elajaili, Faye Walker, Dong Wang, Eva S. Nozik, Siddhartha S. Mitra, Nathan A. Dahl, Rajeev Vibhakar, Sujatha Venkataraman
Journal: Clinical Cancer Research (2022)

Abstract Purpose: Tumor relapse after radiotherapy is a major hurdle in treating pediatric H3K27M-mutant diffuse midline gliomas (DMG). Radiotherapy-induced stress increases association of BCL2 family of proteins with BH3 pro-apoptotic activators preventing apoptosis. We hypothesized that inhibition of radiotherapy-induced BCL2 with a clinically relevant inhibitor, venetoclax, will block BCL2 activity leading to increased apoptosis. BCL2 has never been implicated in DMG as a radiotherapy-induced resistant mechanism. Experimental Design: We performed an integrated genomic analysis to determine genes responsible for radioresistance and a targeted drug screen to identify drugs that synergize with radiation in DMG. Effect of venetoclax on radiation-naïve and 6 Gy radiation on cells was evaluated by studying cell death, changes in BCL2 phosphorylation, reactive oxygen species (ROS), and apoptosis, as well as BCL2 association with BH3 apoptosis initiators. The efficacy of combining venetoclax with radiation was evaluated in vivo using orthotopic xenograft models. Results: BCL2 was identified as a key regulator of tumor growth after radiation in DMGs. Radiation sensitizes DMGs to venetoclax treatment independent of p53 status. Venetoclax as a monotherapy was not cytotoxic to DMG cells. Postradiation venetoclax treatment significantly increased cell death, reduced BCL2–BIM association, and augmented mitochondrial ROS leading to increased apoptosis. Combining venetoclax with radiotherapy significantly enhanced the survival of mice with DMG tumors. Conclusions: This study shows that venetoclax impedes the antiapoptotic function of radiation-induced BCL2 in DMG, leading to increased apoptosis. Results from these preclinical studies demonstrate the potential use of the BCL2 inhibitor venetoclax combined with radiotherapy for pediatric DMG.
Abstract ES12-2: Single cell analysis of circulating tumor cells
Authors: S Maheswaran, R Ebright, D Micalizzi, None D, M Toner, D Haber
Journal: Cancer Research (2022)

Abstract Epithelial to mesenchymal plasticity (EMP), an embryonic process, is reinstated in cancer and has been implicated in tumor metastasis and drug resistance. Tumor cells circulating in the blood of breast cancer patients show extensive EMP with dynamic shifts from one state to another. Comparison of the molecular characteristics of epithelial and mesenchymal circulating tumor cell (CTC) populations shows that epithelial CTCs compared with mesenchymal CTCs express multiple structural ribosomal proteins and exhibit enrichment of translational signatures; these epithelial CTCs are more proliferative and their presence in the blood correlates with poor clinical outcome. Mechanistically, overexpression of a single structural ribosomal protein, RPL15, which encodes a component of the large ribosomal subunit, increased the expression of multiple structural ribosomal proteins, global translation and cell proliferation coinciding with increased metastatic growth in multiple organs. Tumors overexpressing RPL15 were more sensitive to translational inhibitors suggesting that therapies targeting translation in this aggressive subset of epithelial CTCs may serve as potential suppressors of metastatic progression of breast cancer. Citation Format: S Maheswaran, R Ebright, D Micalizzi, D , M Toner, D Haber. Single cell analysis of circulating tumor cells [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr ES12-2.